entX’s medical isotope business, IsoMedica, continues to make strong progress within the Company’s Greenfields-based facility, marking an important milestone in the long-term growth strategy and commitment to advancing radiopharmaceutical manufacturing capability in Australia.

The Greenfields location will house the Advanced Radioisotope Production Facility, which has been purpose-designed to support IsoMedica’s expanding portfolio and future commercialisation objectives. Recent months have seen steady momentum across planning, design refinement and early development activities, laying the groundwork for a highly specialised, scalable operation.

Once complete, the facility will play a critical role in strengthening IsoMedica’s end-to-end capabilities, supporting increased production capacity and enabling greater flexibility as programs progress from development through to commercial readiness. It is a key enabler of the company’s vision to deliver reliable, high-quality solutions that meet the evolving needs of clinical, research and industry partners.

Importantly, the Greenfields project reflects IsoMedica’s focus on future-proofing its operations. The facility has been planned with scalability, compliance and operational efficiency at its core, ensuring it can adapt as demand grows and new opportunities emerge within the radiopharmaceutical market.

This development also represents a significant investment in local capability, reinforcing IsoMedica’s commitment to building sovereign manufacturing infrastructure and contributing to Australia’s advanced manufacturing and nuclear medicine ecosystem.

As work continues, IsoMedica will share updates as key milestones are reached. The Greenfields facility is more than a new site; it is a foundation for the next phase of IsoMedica’s growth and impact.